Try our medicine search tool Aetna prescription plans cover thousands of drugs
Most adverse events are mild to moderate in severity and resolve without stopping the medication
AstraZeneca has licensed ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA), from Eccogene for the treatment of obesity, type 2 diabetes, and other cardiometabolic conditions
This test maps 14 distinct metabolic pathways and 49 peptides to identify which GLP-1 formulation may work most effectively for your unique biology
These mechanisms remain the subject of ongoing laboratory and preclinical research
Historically, clinical endpoints such as response rates, progression-free survival, and overall survival have dominated clinical research